Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study

Ravulizumab (ALXN1210), a new complement C5 inhibitor, provides immediate, complete, and sustained C5 inhibition. This phase 3, open-label study assessed the noninferiority of ravulizumab to eculizumab in complement inhibitor–naive adults with paroxysmal nocturnal hemoglobinuria (PNH). Patients with...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood
Auteurs principaux: Lee, Jong Wook, Sicre de Fontbrune, Flore, Wong Lee Lee, Lily, Pessoa, Viviani, Gualandro, Sandra, Füreder, Wolfgang, Ptushkin, Vadim, Rottinghaus, Scott T., Volles, Lori, Shafner, Lori, Aguzzi, Rasha, Pradhan, Rajendra, Schrezenmeier, Hubert, Hill, Anita
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2019
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6367644/
https://ncbi.nlm.nih.gov/pubmed/30510080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-09-876136
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires